SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Mike McFarland who wrote (536)4/27/1999 11:45:00 PM
From: Gunter RICHTER  Read Replies (1) | Respond to of 4474
 
Finally a statement worth 5 cents. Ariad , as a stock play is dead. The company does not have the internal science -to- marketable product infrastructure nor the prowess to raise or manage its cash reserves( for a finance expert, their financial underbelly is a horror story) Ariad as we know it could not bring anything to market. Some of its work will be picked up, combined with other findings and a real pharmaceutical company will eventually bring out a usable product. A Mickey Mouse boutique lab, even with talented scientists toiling away, will not rise up to be a pharmaceutical company over night. The Ariad story is over.



To: Mike McFarland who wrote (536)8/4/1999 3:51:00 AM
From: Mike McFarland  Respond to of 4474
 
NF-kappaB Regulation and Function:
From Basic Research to Drug Development

symposia.com

("ARIAD is pursuing a series of related patent applications
on NF-kB, to which it holds an exclusive license.")

I do not see anybody from Ariad on the program yet,
but it is still early--David Baltimore is at the top
of the schedule however.

The NF-kB family of transcription factors and the signaling pathway that regulates their activity have become a classical paradigm in modern cell biology. Not only do we know most members of this family, we also know their three dimensional structure, their physiological function and how they are regulated. The major signaling pathway leading to NF-kB activation has been elucidated as well, and the function of its key players determined genetically. The NF-kB pathway has emerged as a major regulator of the inflammatory and innate immune responses as well as a major controller of cell life and death. It still remains to be identified how individual members of the NF-kB family execute more specific and restricted biological decisions. In addition to the control of basic physiological processes, aberrant regulation of NF-kB activity is suspected to be involved in a variety of severe pathologies, including inflammatory and autoimmune disease, neurodegenerative disease and cancer. There is a great demand for development of specific inhibitors of the NF-kB pathway, but we will have to learn carefully how to use them. This meeting will bring together leading scientists involved in basic research into NF-kB function and regulation, its involvement in disease and development of various strategies to inhibit NF-kB activation.